{
  "asset": "Bleximenib",
  "query_terms": [
    "Bleximenib"
  ],
  "returned_unique": 5,
  "kept": 5,
  "studies": [
    {
      "nct_id": "NCT06852222",
      "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Bleximenib",
        "Venetoclax (VEN)",
        "Azacitidine (AZA)",
        "Placebo"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06852222"
    },
    {
      "nct_id": "NCT07295951",
      "title": "An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Leukemias",
        "Acute Myeloid Leukemia"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "14C-bleximenib",
        "bleximenib"
      ],
      "last_update": "2025-12-22",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07295951"
    },
    {
      "nct_id": "NCT05453903",
      "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Bleximenib",
        "Venetoclax (VEN)",
        "Azacitidine (AZA)",
        "Cytarabine",
        "Daunorubicin or Idarubicin"
      ],
      "last_update": "2025-12-24",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05453903"
    },
    {
      "nct_id": "NCT04811560",
      "title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Acute Leukemias",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Bleximenib"
      ],
      "last_update": "2025-12-10",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04811560"
    },
    {
      "nct_id": "NCT07223814",
      "title": "Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "lead_sponsor": "Stichting Hemato-Oncologie voor Volwassenen Nederland",
      "collaborators": [
        "German-Austrian Acute Myeloid Leukemia Study Group"
      ],
      "interventions": [
        "Bleximenib",
        "Cytarabine",
        "Daunorubicin or Idarubicin",
        "Placebo"
      ],
      "last_update": "2025-11-03",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07223814"
    }
  ]
}